Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Randomized, Two-way Crossover, Bioequivalence Study in Healthy Volunteers to Compare the Pharmacokinetics of Two Different Tablets of Sotorasib

Next Previous
X
Search
Trial Profile

An Open-label, Randomized, Two-way Crossover, Bioequivalence Study in Healthy Volunteers to Compare the Pharmacokinetics of Two Different Tablets of Sotorasib

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sotorasib (Primary)
  • Indications Brain metastases; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Amgen

    • Most Recent Events

    • 29 Mar 2024 Results Comparing the Pharmacokinetics of Two Different Tablet Strengths of Sotorasib in the Fed and Fasted State presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 24 Mar 2023 Results presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 07 Feb 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top